The CurePSP Genetics Program
Public ClinicalTrials.gov record NCT06647641. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.
Study identification
- NCT ID
- NCT06647641
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
- PSP
- PSP - Progressive Supranuclear Palsy
- Corticobasal Syndrome
- Corticobasal Syndrome(CBS)
- Corticobasal Degeneration Syndrome
- Corticobasal Degeneration
- Corticobasal Degeneration (CBD)
- Corticobasal Syndrome (CBS)
- MSA
- MSA - Multiple System Atrophy
- MSA-C
- Multiple System Atrophy
- Multiple System Atrophy (MSA) With Orthostatic Hypotension
- Multiple System Atrophy - Cerebellar Subtype (MSA-C)
- Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
- Multiple System Atrophy, Cerebellar Type
- Multiple System Atrophy, Parkinsonian Type
- Progressive Supranuclear Palsy
- Progressive Supranuclear Palsy(PSP)
- Progressive Supranuclear Palsy (PSP)
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2024
- Primary completion
- Dec 30, 2028
- Completion
- Dec 30, 2030
- Last update posted
- Jan 13, 2026
2024 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06647641, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06647641 live on ClinicalTrials.gov.